We summarise key insights from the pharmaceutical, pricing and market access sector:
News:
- Kidney Research UK deems NICE process “not appropriate for a rapidly evolving virus
- Sharp criticism is received for the increased VPAS clawback rate of 26.5% in 2023
- Health benefits paid by supplementary bodies jumped by 11.6% last year
Our Latest Articles:
- EU HTA – looking back on 2022
- Effective P & R Processes to Ensure the Future of Gene Therapies in the EU – a 2022 review
- Reflecting on the pricing and market access trends that shaped 2022